Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Crestwood Advisors Group LLC

Crestwood Advisors Group LLC lessened its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 48.6% during the second quarter, Holdings Channel.com reports. The institutional investor owned 5,245 shares of the biopharmaceutical company’s stock after selling 4,956 shares during the period. Crestwood Advisors Group LLC’s holdings in Bristol-Myers Squibb were worth $218,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. ESL Trust Services LLC acquired a new stake in Bristol-Myers Squibb during the 1st quarter valued at $27,000. Northwest Financial Advisors acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at $27,000. Pacific Capital Wealth Advisors Inc. acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at $34,000. Fairman Group LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at $42,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb during the 1st quarter valued at $47,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 1.2 %

Shares of BMY opened at $50.54 on Wednesday. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86. The firm has a market capitalization of $102.45 billion, a P/E ratio of -16.30, a price-to-earnings-growth ratio of 12.92 and a beta of 0.44. The stock’s fifty day simple moving average is $45.49 and its 200 day simple moving average is $46.56. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $62.00.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The company had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. During the same period last year, the company posted $1.75 earnings per share. The firm’s revenue was up 8.7% compared to the same quarter last year. On average, equities research analysts forecast that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 4.75%. The ex-dividend date was Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on BMY shares. Barclays raised their price objective on Bristol-Myers Squibb from $41.00 to $42.00 and gave the stock an “underweight” rating in a report on Thursday, August 22nd. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Jefferies Financial Group raised their price objective on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft decreased their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd. Finally, TD Cowen raised their price objective on Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a report on Monday, August 12th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $54.67.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.